Characterization, in Vitro and in Vivo Evaluation of Naringenin-Hydroxypropyl-β-Cyclodextrin Inclusion for Pulmonary Delivery
Open Access
- 28 January 2020
- Vol. 25 (3), 554
- https://doi.org/10.3390/molecules25030554
Abstract
Naringenin, a flavonoid compound which exists abundantly in Citrus fruits, is proven to possess excellent antitussive and expectorant effects. However, the clinical applications of naringenin are restricted by its poor solubility and low local concentration by oral administration. The aim of the present study is to prepare a naringenin-hydroxypropyl-β-cyclodextrin (naringenin-HPβCD) inclusion as an inhalation solution for pulmonary delivery. The naringenin-HPβCD inclusion was characterized by phase solubility study, XRD, differential scanning calorimetry (DSC), proton nuclear magnetic resonance (1HNMR), and two-dimensional rotating frame Overhauser effect spectroscopy (2D ROESY). The in vitro permeability of the inclusion was evaluated on Calu-3 cells and the pharmacokinetic profile of pulmonary delivery was investigated in Sprague-Dawley (SD) rats. Based on the linear model of phase solubility study, the relationship between naringenin and HPβCD was identified as AL type with a 1:1 stoichiometry. XRD, DSC, and NMR studies indicated that the entire naringenin molecule is encapsulated into the cavity of HPβCD. HPβCD could increase the concentration of naringenin in the epithelium-lining fluid (ELF) of Calu-3 cells and act as a sustained release system for naringenin. The pharmacokinetic profile of naringenin-HPβCD inclusion showed rapid response and higher local concentration by pulmonary delivery. In conclusion, pulmonary delivery of naringenin-HPβCD inclusion is a promising formulation strategy, which could provide a new possibility for the clinical application of naringenin.This publication has 37 references indexed in Scilit:
- Regulation effects of naringin on diesel particulate matter-induced abnormal airway surface liquid secretionPhytomedicine, 2019
- Naringenin Regulates CFTR Activation and Expression in Airway Epithelial CellsCellular Physiology and Biochemistry, 2017
- Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokineticsDrug Design, Development and Therapy, 2016
- Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthmaPulmonary Pharmacology & Therapeutics, 2015
- Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design, characterization,in vitroandin vivoevaluationDrug Delivery, 2013
- Anti-Inflammatory Effects of Naringin in Chronic Pulmonary Neutrophilic Inflammation in Cigarette Smoke-Exposed RatsJournal of Medicinal Food, 2012
- Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathwaysEuropean Journal of Pharmacology, 2012
- Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smokeInternational Immunopharmacology, 2012
- Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathwayInternational Immunopharmacology, 2011
- The expectorant activity of naringeninPulmonary Pharmacology & Therapeutics, 2008